Format

Send to

Choose Destination
FASEB J. 2018 Jan;32(1):5-15. doi: 10.1096/fj.201700325R. Epub 2017 Nov 1.

Application and utility of mass cytometry in vaccine development.

Author information

1
Vaccine and Immunotherapy Center, Massachusetts General Hospital-East, Boston, Massachusetts, USA; and.
2
InnatOss, Oss, The Netherlands.
3
Vaccine and Immunotherapy Center, Massachusetts General Hospital-East, Boston, Massachusetts, USA; and mpoznansky@partners.org.

Abstract

Mass cytometry enables highly multiplexed profiling of cellular immune responses in limited-volume samples, advancing prospects of a new era of systems immunology. The capabilities of mass cytometry offer expanded potential for deciphering immune responses to infectious diseases and to vaccines. Several studies have used mass cytometry to profile protective immune responses, both postinfection and postvaccination, although no vaccine-development program has yet systematically employed the technology from the outset to inform both candidate design and clinical evaluation. In this article, we review published mass cytometry studies relevant to vaccine development, briefly compare immune profiling by mass cytometry to other systems-level technologies, and discuss some general considerations for deploying mass cytometry in the context of vaccine development.-Reeves, P. M., Sluder, A. E., Raju Paul, S., Scholzen, A., Kashiwagi, S., Poznansky, M. C. Application and utility of mass cytometry in vaccine development.

KEYWORDS:

CyTOF; biomarker discovery; flow cytometry

PMID:
29092906
DOI:
10.1096/fj.201700325R
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center